ORCHPHARMANSEOrchid Pharma LimitedHighNeutral
Announced Wed, 18 Mar · 21:33 IST

Orchid Pharma Limited has informed the Exchange regarding 'Update on Scheme of arrangement'.

Nclt Scheme FiledStrategic Transactions View source PDF

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.0%1-day move
₹540.00
prior close
₹527.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+1.0+0.7+0.6-2.0-5.6-5.1-1.3-6.7-5.2+5.1+0.5+36.1+79.7
Up moveDown movePending
AI summary

Orchid Pharma Limited informed the exchanges that the NCLT (National Company Law Tribunal) has reserved its order on the Scheme of Amalgamation of Dhanuka Laboratories Limited into Orchid Pharma Limited. The order was reserved for formal pronouncement on March 18, 2026, meaning the tribunal has finished hearing the matter and the verdict is awaited. The company will share the NCLT order copy with the exchanges and on its website once received. This is a continuation of earlier intimations regarding the pending merger petition.

Likely market impact

The NCLT reserving its order is a key milestone — a favourable order will complete the legal merger of Dhanuka Laboratories into Orchid Pharma, potentially expanding the combined business. Shareholders should watch for the formal order, which could act as a short-term catalyst for the stock depending on the outcome.